Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Chimeric Therapeutics Ltd. ( (AU:CHM) ) is now available.
Chimeric Therapeutics has issued 309,900,722 new ordinary shares on 7 January 2026, expanding its share capital without providing a prospectus-style disclosure under the Corporations Act provisions governing fundraising. The company affirmed it is up to date with its financial reporting and continuous disclosure obligations and stated that there is no excluded information requiring disclosure, signalling regulatory compliance around the capital issuance for existing and prospective investors.
The most recent analyst rating on (AU:CHM) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on Chimeric Therapeutics Ltd. stock, see the AU:CHM Stock Forecast page.
More about Chimeric Therapeutics Ltd.
Chimeric Therapeutics Limited (ASX: CHM) is an Australian biotechnology company operating in the therapeutic sector, focused on developing innovative medical treatments. It is listed on the Australian Securities Exchange and issues ordinary shares as its primary equity instrument to fund operations and growth.
Technical Sentiment Signal: Sell
Current Market Cap: A$12.33M
Find detailed analytics on CHM stock on TipRanks’ Stock Analysis page.